ViiV Healthcare, a global leader in HIV care and research, will present significant research findings at the 19th Annual European AIDS Conference (EACS 2023) in Warsaw, Poland from October 18-21, 2023. The company, primarily owned by GSK with Pfizer and Shionogi as shareholders, is dedicated to addressing the evolving needs of the HIV community. Key data to be presented includes long-term and real-world research on their portfolio of approved and investigational HIV medicines, encompassing long-acting and 2-drug regimens. Key highlights include:
- Clinical and Real-World Evidence: ViiV Healthcare will introduce real-world data on Vocabria (cabotegravir injection) and Rekambys (rilpivirine long-acting injectable suspension) (CAB+RPV LA) across Europe. These findings stem from the SOLAR study, the first phase IIIb study of the full long-acting injectable regimen compared to daily oral Biktarvy.
- 2-Drug Regimen Insights: Dovato (dolutegravir, lamivudine [DTG/3TC]) will be explored in a real-world German cohort to assess its effectiveness, safety, and tolerability over three years. Additional data will delve into DTG/3TC in populations over 50, treatment-naïve individuals with specific baseline conditions, and more.
- Long-Term Data: The phase III BRIGHTE clinical trial’s five-year results, focusing on the use of Rukobia (fostemsavir) in heavily treatment-experienced (HTE) populations with multi-drug resistant HIV-1, will be discussed. New data will offer insights into fostemsavir’s long-term safety and its impact on immune recovery and inflammation-related biomarkers in these patients.
- Innovative HIV Research: The BANNER study’s findings on N6LS (VH3810109), a novel, investigational, broadly neutralizing antibody (bNAb), will be introduced. This component of ViiV Healthcare’s ultra-long-acting medicine strategy is being explored for dosing intervals of at least every four months.
These research presentations demonstrate ViiV Healthcare’s commitment to enhancing the quality of life for those living with HIV by exploring innovative treatments and regimens.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
